期刊文献+

端粒酶逆转录酶基因启动子调控的肿瘤细胞特异表达载体的构建和鉴定 被引量:3

Construction and identification of a tumor-specific expression vector driven by human telomerase reserve transcriptase gene promotor
原文传递
导出
摘要 目的 利用端粒酶逆转录酶基因启动子 ,构建能在人肿瘤细胞中特异表达目的基因的表达载体。方法 通过PCR方法从 pEGFP N1质粒中扩增出绿色荧光蛋白基因并克隆到逆转录病毒载体pLNCX的多克隆位点上 ,命名为 pLNCX EGFP。设计含有特定酶切位点的引物 ,从人基因组中扩增出端粒酶逆转录酶基因启动子序列 ,将该序列片段定向克隆到已用限制性内切酶切除巨细胞病毒启动子的 pLNCX EGFP载体上 ,构建成端粒酶逆转录酶基因启动子调控的含有绿色荧光蛋白报告基因的表达载体 pLNT EGFP。将该表达载体pLNT EGFP瞬时转染高表达端粒酶活性的HLF细胞株和不表达端粒酶活性的WI38细胞株 ,以检测端粒酶逆转录酶基因启动子的转录活性。结果 表达载体pLNT EGFP经酶切、测序分析证实与设计的完全一致。细胞瞬时转染结果表明 ,pLNT EGFP能特异地在端粒酶阳性细胞中高效表达绿色荧光蛋白报告基因 ,而在端粒酶阴性细胞中不表达报告基因。结论 成功构建了由端粒酶逆转录酶基因启动子调控的肿瘤细胞靶向表达载体。 Objective To construct the tumor-specific expression vector driven by human telomerase reserve transcriptase gene promotor. Methods The fragment of the enhanced green fluorescent protein (EGFP) gene was PCR amplified from the pEGFP-N1 plasmid and cloned into the multiple cloning site of pLNCX vector, and the recombinant was named as pLNCX-EGFP. The fragment of human telomerase reserve transcriptase gene promoter was amplified from the human genome by using the human telomerase reserve transcriptase gene specific primers, and cloned into the pLNCX-EGFP vector, where the cytomegalovirus promoter was previously removed using restriction enzymes, in sense orientation relative to the green fluorescent protein coding sequence. Then the expression vector pLNT-EGFP under the control of the human telomerase reserve transcriptase gene promoter, containing green fluorescent protein reporter gene, was successfully constructed. To detect the transcriptional activity of the human telomerase reserve transcriptase gene promoter, transient transfection of this specific expression vector into HLF cell lines with high telomerase activity and WI38 cell lines without telomerase activity was performed. Results The expression vector proven by restriction enzymes digestion and sequencing was in correspondence with the design. The results of transient transfection showed that the pLNT-EGFP vector could highly expressed green fluorescent protein reporter gene in telomerase-positive cells, but not in telomerase-negative cells. Conclusion A tumor-specific expression vector driven by human telomerase reserve transcriptase gene promotor has been successfully constructed.
出处 《中华医学杂志》 CAS CSCD 北大核心 2003年第14期1274-1277,共4页 National Medical Journal of China
关键词 端粒酶 逆转录酶基因 肿瘤细胞特异表达载体 鉴定 基因治疗 恶性肿瘤 克隆 Telomerase Promoter regions (Genetics) Gene therapy
  • 相关文献

参考文献12

  • 1Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science, 1994,266:2011-2015.
  • 2Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer, 1997,33:787-791.
  • 3Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene, 1999,232:97-106.
  • 4Kondo S, Tanaka Y, Kondo Y, et al. Retroviral transfer of CPP32beta gene into malignant gliomas in vitro and in vivo. Cancer Res, 1998,58:962-967.
  • 5Blackburn EH. Structure and function of telomeres. Nature, 1991,350:569-573.
  • 6Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer, 1997,33:781-786.
  • 7Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science, 1998,279:349-352.
  • 8Horikawa I, Cable PL, Afshari C, et al. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res, 1999,59:826-830.
  • 9Takakura M, Kyo S, Kanaya T, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res, 1999,59:551-557.
  • 10Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 1997,90:785-795.

同被引文献29

  • 1黄慧敏,张红,李惠翔,姜国忠,高冬玲,王秀利.表达E2F1小干扰RNA的逆转录病毒载体的构建[J].实用诊断与治疗杂志,2005,19(3):177-179. 被引量:5
  • 2Gu J,Fang B.Telomerase promoter driven cancer gene therapy.Cancer Biol Ther,2003,2:64-70.
  • 3Wirth T,Kühnel F,Kubicka S.Telomerase-dependent gene therapy.Curr Mol Med,2005,5:243-251.
  • 4Shinoura N,Hamada H.Gene therapy using an adenovirus vector for apoptosis-related genes is a highly effective therapeutic modality for killing glioma cells.Curr Gene Ther,2003,3:147-153.
  • 5Chen RF,Li ZH,Pan QH,et al.In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.Pancreatology,2007,7:505-513.
  • 6Schwabe M,Lübbert M.Epigenetic lesions in malignant melanoma.Curr Pharm Biotechnol,2007,8:382-387.
  • 7Milner J. RNA interference for treating cancers caused by viral infection. Expert Opin Biol Ther, 2003,3 (3) :459.
  • 8Xia HB, Mao QW, Paulson HL, et al. SiRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol, 2002,20(10) :1 006.
  • 9Aoki K, Yoshida T, Sugimura T, et al. Liposome-mediated in vivo gene transfer of antisense K-ras construction inhibits pancreatic tumor dessemination in the murine peritoneal cavity. Cancer Res,1995,55(17):3 810.
  • 10Svoboda P,Stein P,Schultz RM. RNAi in mouse oocytes and preimplantation embryos: effectiveness of hairpin dsRNA.Biochem Biophys Res Commun, 2001,287(5) :1099.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部